Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD1 Armored CD19 CAR-T Cells in r/r DLBCL
NCT07368270Phase 1Recruiting
- Sponsor
- Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-programmed cell death protein 1 armored CD19 chimeric antigen receptor T cells in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd. Primary endpoints: Incidence of dose-limiting toxicity at 1 month and Adverse Events and Serious Adverse Events at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
anti-programmed cell death protein 1 armored CD19 chimeric antigen receptor T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07368270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07368270.